Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

asx bct

  • Home
  •  
  • asx bct



  • Most Read
  • Latest Comments
  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PainChek locks in performance data for FDA submission, aiming to be  first pain assessment app approved in US
    PainChek locks in performance data for FDA submission, aiming to be first pain assessment app approved in US
    • News

  • HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    • News

  • Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24
    • News

    Direct marketing of biotags and global expansion mark BlueChiip’s cheery entry into FY24

    A blue chip denotes the cream of the crop—the most put-together, high-quality company or share. So one can only imagine that naming your company Bluechiip would entail high expectations. And high pressure. Two years ago, advanced sampling management company Bluechiip (ASX: BCT) announced that it would directly market its Bluechiip-Enabled products to end-users, concentrating especially

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.